Review top news and interview highlights from the week ending September 22, 2023.
Lysosomal Disorders
Latest News
Advertisement
CME Content
Advertisement
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The PDUFA data has been set for March 18, 2024.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending September 8, 2023.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The data come from 30 patients treated across 2 clinical trials and 9 patients treated in expanded access frameworks who had follow-up times ranging from 0.64 years to 12.19 years.
Phase 1/2 trials have been cleared in Germany and dosed first patients in the US.
Review top news and interview highlights from the week ending September 1, 2023.
In recent data from the phase 3 VITAL trial, EB-101 decreased pain and improved wound healing.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Review top news and interview highlights from the week ending August 25, 2023.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Earlier this year Bloomsbury Genetic Therapies met with the UK’s MHRA for a scientific advice meeting to discuss BGT-NPC.
The company announced that it had completed dosing in the first cohort of the GALILEO-1 trial of FLT201.
BGT-OTCD is being developed in a collaboration between Bloomsbury Genetic Therapies and University College London.
NGN-101 will be delivered to each participant via both intracerebroventricular and intravitreal routes on the same day in the phase 1/2 trial, with the therapy assessed for safety and efficacy.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
The pediatric gastroenterologist and professor in residence at University of California at San Francisco discussed challenges with clinical trials in neurocognitive diseases including MPS2.
At dose level 2, 3 of 4 participants had increases of β-Gal activity to normal levels for up to 12 months.
Review top news and interview highlights from the week ending August 4, 2023.
The gene-edited cell therapy OTL-200 was approved in Europe in 2020.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
LEXEO also recently completed dosing in the first cohort of a trial for Friedreich’s ataxia cardiomyopathy.
The first-in-human MuST trial is being conducted in several centers in Germany.
Advertisement
Advertisement
Trending on CGTlive®
1
Evaluating Gene Editing Therapy Reni-Cel for Severe Sickle Cell Disease
2
Steven W. Pipe, MD, on the End-of-Study Results From Hemgenix’s HOPE-B Trial
3
Rabi Hanna, MD, on Practical Considerations for Integrating Gene Therapy
4
MDA 2026 to Bring Keynote Insights and Evolving Neuromuscular Care
5
